Cognitive
PE-22-28
per administration
Only animal or lab studies exist — no human study has set an amount.
Quick start
PE-22-28 at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 100–300 mcg per administration
- How often
- Every day
- Where
- Commonly subcutaneous Sites and rotation
- Time to steady level
- ~5 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for PE-22-28 describe 100–300 mcg per administration. Descriptive only, not a recommendation.
Spadin itself clears within minutes; the PE 22-28 analog was engineered for greater stability, but human pharmacokinetics are unpublished, so this is a rough placeholder.
Evidence is preclinical: a shortened, stabilised analog of spadin that blocks the TREK-1 potassium channel, studied in rodent mood and neurogenesis models. No human dose-ranging data fixes an amount or schedule and the figures are community-derived, so no schedule table is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 5hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- PE 22-28 / spadin TREK-1 literature (Mazella/Borsotto)A spadin-derived TREK-1 blocker reported to raise neurogenesis and antidepressant-like activity in mice; no human dosing literature.